In 1996, it was changed to a joint-stock system. Restructured into a purely private enterprise in 2007, the newly planned Sifang New Industrial Park covers an area of ??more than 200 acres, has advanced production technology, production equipment and GMP standard workshops, with total assets of 160 million, and currently has 680 employees, including 15 with senior professional titles. There are 71 intermediate professional titles and 318 professional technical personnel.
The company has always adhered to the business philosophy of "serving the public from all over the world and creating a healthy life", inheriting and developing the glorious history of Zhoukou Medical Glue. There are currently more than 60 varieties in seven major dosage forms. The main products include Sifang brand donkey-hide gelatin blood-enhancing ointment, donkey-hide gelatin blood-enhancing oral liquid, turtle shell glue, deer antler glue, turtle shell glue, Xiaoke Tongmai oral liquid, compound platycodon cough tablets, etc. New national-level products such as Qianlietong Capsules, Xiaoaiping Oral Liquid, Gujin Pills, and Changweining Tablets were launched. The product structure is reasonable, and some products are exported to Southeast Asian countries and regions. Donkey-hide gelatin blood-tonifying ointment ranks at the top of single-type sales in the current domestic blood-tonifying market. The glue series products with donkey skin donkey-hide gelatin as the leader have won provincial, ministerial, and provincial awards fifteen times. The national gold medal "Baokang" and "Chengda" were selected as selected trademarks by the State Administration for Industry and Commerce. In recent years, the company has extensively integrated social science and technology advantageous resources and integrated industry, academia and research. It has established close technical cooperation relationships with nearly 50 scientists from six domestic first-class universities and institutes in Shanghai and Beijing, and has its own independent scientific research institution to Promote the industrialization of various technological achievements. The newly developed new drug "Xiaoke Tongmai Oral Liquid" will soon become a new economic growth point for the company's development.
In the context of fierce competition in the pharmaceutical market, the company has proposed a long-term development strategic plan focusing on the development opportunities of "second entrepreneurship". In line with the principles of high-level design, high starting point for construction, and as large a scale as possible, we have invested in the construction of a 3 million box Xiaoke Tongmai oral liquid production line and a traditional Chinese medicine modernization expansion project. It has created a good development platform for the company. The project can produce 1 billion Chinese patent medicine tablets, 500 tons of granules, 300 million capsules, 100 million oral liquids, and 5 million bottles of decoctions annually, which will double the current production.
The company is moving towards an international, standardized and modern large-scale pharmaceutical enterprise group. Sifang Pharmaceutical Group will create the glory of modern traditional Chinese medicine with its century-old pharmaceutical glory.